Study Background Allucent was selected to provide full-service support for a Phase IIb randomized clinical trial in patients with first line metastatic head and neck squamous cell carcinoma (HNSCC) for a leading global biopharma company. The global study was conducted across 31 sites in multiple countries and regions and enrolled 171 patients. Key study activities […] The post Achieving Critical Database Lock Milestones in a Global Oncology Study appeared first on Allucent .